ATAI Life Sciences N.V. (ATAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATAI Stock Price Chart Interactive Chart >
ATAI Price/Volume Stats
|Current price||$4.07||52-week high||$22.91|
|Prev. close||$3.90||52-week low||$3.05|
|Day high||$4.09||Avg. volume||907,005|
|50-day MA||$4.58||Dividend yield||N/A|
|200-day MA||$9.20||Market Cap||654.18M|
ATAI Life Sciences N.V. (ATAI) Company Bio
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Most Popular Stories View All
ATAI Latest News Stream
|Loading, please wait...|
ATAI Latest Social Stream
View Full ATAI Social Stream
Latest ATAI News From Around the Web
Below are the latest news stories about ATAI Life Sciences NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health company, atai Life Sciences - Funds will help support the general operations of MAPS, including its Health Equity Program to increase diversity, equity and inclusion in psychedelic healthcare NEW YORK and BERLIN, Feb. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic program of atai Life Scienc
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February. Presentation details can be found below: Aegis ConferenceFormat: VirtualDate and Time: Thursday, February 24, 2022, 11:30 a.m. ETWebcast Link: https://bit.ly/3JuuKmV The presentations and archived webcasts will also be accessi
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ATAI Life Sciences (ATAI – Research Report), BioNTech SE (BNTX – Research Report) and Seagen (SGEN – Research Report) with bullish sentiments. ATAI Life Sciences (ATAI) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on ATAI Life Sciences, with a price target of $50.00. The company's shares closed last Tuesday at $5.39, close to its 52-week low of $5.29. According to TipRanks.
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
• Enables expansion of PCN-101 clinical development to the U.S. • atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs • DDI trial will complement existing Phase 2a trial in treatment-resistant depression (TRD) recently initiated in Europe NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform
NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: H.C. Wainwright BioConnect Conference (Virtual)Format: Fireside ChatDate and Time: Monday, January 10th, 2022, 2:00 p.m. ETWebcast Link: URL The presentations and archived webcasts will also be accessible in the Events section of at
ATAI Price Returns